Next Article in Journal
Cell Counting and Cell Cycle Analysis of Simple Non-Cultured Endothelial Cell Injection (SNEC-I) Therapy: Characterization for Clinical Translation
Previous Article in Journal
Radioligands Targeting the Purinergic P2X Receptors
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cells
Volume 14
Issue 13
10.3390/cells14130985
cells-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Local T-Cell Dysregulation and Immune Checkpoint Expression in Human Papillomavirus-Mediated Recurrent Respiratory Papillomatosis

by
Hans N. C. Eckel
1,2,*,†,
Su Ir Lyu
3,†,
Frederik Faste
1,2,
Shachi J. Sharma
1,2,
Anne Nobis
1,2,
Nora Wuerdemann
2,4,
Maria Ziogas
1,2,
Marcel Mayer
1,2,
Malte C. Suchan
1,2,
Kerstin Wennhold
2,
Maria A. Garcia-Marquez
2,
Martin Thelen
2,
Elena Hagen
2,5,
Julia Eßer
1,2,
Charlotte Klasen
1,2,
Oliver Siefer
2,
Martin Otte
1,2,
Hans A. Schloesser
2,5,
Jens P. Klussmann
1,2,
Alexander Quaas
3 and
Kevin K. Hansen
1,2add Show full author list remove Hide full author list
1
Faculty of Medicine and University Hospital of Cologne, Department of Otorhinolaryngology, Head and Neck Surgery, University of Cologne, 50931 Cologne, Germany
2
Center for Molecular Medicine Cologne, Faculty of Medicine and University Hospital of Cologne, University of Cologne, 50931 Cologne, Germany
3
Faculty of Medicine and University Hospital of Cologne, Institute of Pathology, University of Cologne, 50937 Cologne, Germany
4
Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, 50937 Cologne, Germany
5
Faculty of Medicine and University Hospital of Cologne, Department of General, Visceral, Cancer and Transplantation Surgery, University of Cologne, 50937 Cologne, Germany
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Cells 2025, 14(13), 985; https://doi.org/10.3390/cells14130985
Submission received: 19 May 2025 / Revised: 14 June 2025 / Accepted: 17 June 2025 / Published: 27 June 2025
(This article belongs to the Section Cellular Immunology)
Browse Figures
Versions Notes

Abstract

Human papillomavirus-mediated recurrent respiratory papillomatosis (RRP) is a premalignant neoplasia of the upper airway characterized by significant dysphonia and respiratory obstruction. Immune checkpoint blockade has emerged as a potential alternative to repeated surgical interventions in RRP. Here, we investigated the intralesional T-cell composition and expression of the immune checkpoints programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) in RRP. We analyzed tissue samples from 30 patients treated at a tertiary care center between 2009 and 2021, including paired samples from individual patients collected at different time points. Immunohistochemical staining was performed for CD4, CD8, CTLA-4, FoxP3, and PD-L1 and correlated with disease severity and previous adjuvant therapies. Overall disease burden and intervention-free survival were not associated with the abundance of CD4+, CD8+, or FoxP3+ T cells, nor with immune checkpoint expression. However, patients with aggressive disease exhibited a higher intralesional FoxP3/CD4 T-cell ratio. Prior intralesional cidofovir treatment was associated with reduced CD4+ T-cell infiltration. These findings suggest that a locally immunosuppressive microenvironment, reflected by an elevated FoxP3/CD4 ratio, contributes to disease severity in RRP. Consistent CTLA-4 expression across all evaluated samples supports further investigation of anti-CTLA-4 therapy, either alone or in combination with other checkpoint inhibitors.

Graphical Abstract

1. Introduction

Recurrent respiratory papillomatosis (RRP) is characterized by the frequent recurrence of benign neoplasms within the respiratory tract caused by mucosal human papillomavirus (HPV) infection. HPVs, double-stranded DNA viruses, establish chronic mucosal infections but rarely cause systemic spread [1]. RRP is most commonly associated with low-risk HPV types 6 and 11, although high-risk HPV 16, 18, 31 and 33 may also be detected in papilloma tissue, albeit less frequently [2]. Canonically, the onset of RRP is bimodal, with two distinct incidence peaks: the first peak in children, typically around age 5, and the second peak in adults, around age 30. Recent data suggest a third peak later in life, at age 64 [3,4,5]. While RRP is generally considered benign, Freeman et al. reported malignant degeneration in 16.3% of smokers and 3.6% of nonsmokers, with other reports estimating the occurrence of malignant transformation in 3 to 7% of RRP cases, classifying RRP as a premalignant condition [6,7,8]. Although RRP primarily affects the upper airways, particularly the membranous vocal folds and false vocal cords, it can spread throughout the respiratory tract, with rare involvement of the trachea, nasopharynx, and lung [9,10,11,12].
Patients with RRP exhibit impaired immune responses to HPV-6 and -11, including preferential differentiation of CD4+ T cells towards T helper 2 lineage and dysfunction in natural killer cells [13]. This may be partly driven by HPV-mediated inhibition of Langerhans cell activation and maturation, resulting in an impaired HPV-specific Th1 response [14]. Furthermore, increased levels of immune checkpoint molecules such as programmed-death ligand 1 and 2 (PD-L1 and PD-L2)—as well as the presence of T-cells expressing programmed cell death protein 1 (PD-1), T-cell immunoreceptor with Ig and ITIM domains (TIGIT), lymphocyte-activation gene 3 (LAG3), and T-cell immunoglobulin and mucin-domain containing-3 (TIM3)—have been described within the RRP lesions [15,16,17]. In summary, RRP is characterized by an immunosuppressive microenvironment with increased expression of immune checkpoint molecules and immunosuppressive cytokines, as well as a marked absence of interferon-gamma (IFN-γ) expression [18,19].
Careful surgical debulking remains the primary treatment for RRP, with options such as CO2-laser surgery and microdebrider-assisted surgical excision commonly employed to maintain airway patency and minimize mucosal damage [20,21,22]. However, due to frequent recurrence, many patients require multiple surgeries to maintain glottic function. Therefore, adjuvant therapies aiming to increase the intervals between surgeries have been tested [23,24,25]. Immune checkpoint blockade (ICB) has emerged as a systemic therapy for hematologic and solid malignancies and provides substantial benefits for patients [26,27]. A phase II study of the PD-L1 inhibitor avelumab in patients with aggressive RRP demonstrated safety and clinical activity, with a significant number of patients showing improvement in disease burden and a reduction in the frequency of surgical interventions, with similar results reported for nivolumab, a PD-1 inhibitor [28,29].
As RRP is a rare but devastating disease, with some patients requiring over 100 procedures in extreme cases, further investigation into novel treatment modalities, including ICB, is warranted to improve patient outcomes and reduce healthcare costs. In this study, we analyzed the T-cell composition and expression of immune checkpoints PD-L1 and cytotoxic lymphocyte antigen 4 (CTLA4), a co-inhibitory molecule not previously investigated in RRP, in a representative cohort of RRP patients in a German tertiary care center.

2. Materials and Methods

2.1. Patient Population and Data Collection

We conducted a retrospective study on a cohort of 30 RRP patients treated and followed up at the University of Cologne. The inclusion criteria for this study were the availability of RRP tissue specimens and available clinical data in patient records. Patients with a histological diagnosis of papilloma and positive HPV 6 or 11 DNA status were included. After reviewing the medical records and availability of RRP tissue specimens of patients with histologically confirmed laryngeal papillomatosis treated between 2009 and 2021, 38 patients were eligible. Of these patients, 30 provided written informed consent and were included in this study. The institutional review board of the University of Cologne approved this study (Review No. 21-1256, dated 17 August 2021). Clinical data collected from medical records included sex, age at initial diagnosis of RRP, lifetime number of needed surgical interventions, tracheal involvement, use of intralesional adjuvant treatment, and HPV vaccination status.

2.2. HPV-DNA Genotyping

HPV-DNA genotyping was performed for all patients using the HPV 3.5 LCD-Array (Chipron GmbH, Berlin, Germany). Extracted DNA was analyzed for the presence of HPV genotypes (6, 11, 16, 18, 31, 33, 35, 39, 42, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 67, 68, 70, 72, 73, 81, 82, 83, 84, 90, 91) using a PCR-based approach, targeting conserved regions of the viral genome. The resulting PCR products were then subjected to hybridization on the HPV 3.5 LCD-Array, followed by a secondary labeling step and subsequent signal detection according to the manufacturer’s instructions. After washing and drying, the arrays were scanned and analyzed using a dedicated imaging system for pattern recognition and genotype identification.

2.3. Immunohistochemistry and Digital Evaluation

Immunohistochemical stainings were carried out in alignment with the manufacturers’ guidelines. The staining panel included CD4, CD8, CTLA4, FoxP3, and PDL1. Additional information about the antibodies is available in Supplementary Table S1. All stainings were performed using the automated Leica BOND-MAX system (Leica Biosystems, Wetzlar, Germany) following the recommended protocols. The resulting slides were digitized with the Aperio GT 450 DX scanner (Leica Biosystems, Wetzlar, Germany). Digital analysis of the stainings was conducted using QuPath v0.3.2, with a customized script adapted from Bankhead et al. [30]. For each slide, ten randomized 250 × 250 µm fields within the papilloma region were selected. Using a trained pixel classifier, the analyzed regions were segmented into epithelium, stroma, and background. Within these classified areas, cells were detected and classified within these compartments to enable independent quantification of positive and negative cells.

2.4. Statistical Analysis

Data processing, statistical analysis, and visualization were conducted using GraphPad Prism version 10.4.0. The differences between individual groups were assessed for significance using the nonparametric Mann–Whitney test. For the RRP cohort, intervention-free survival was defined as time between two surgical interventions. Kaplan–Meier curves were generated, with significance determined by the log-rank test. Patients without events or lost to follow-up were censored at the last known date. p values < 0.05 were considered significant.

3. Results

The study population included a cohort of 30 patients with RRP; 17 (57%) patients were male, while 13 (43%) were female. The median age of the patients at disease onset was 32 years (range 1–61); considering patients below the age of 12 years (juvenile-onset), 4 patients were classified as juvenile-onset, while 26 patients had adult-onset RRP. Fifteen (50%) patients had received intralesional injection of either bevacizumab or cidofovir, and six (20%) had received HPV vaccination (either Gardasil® or Gardasil 9®). Patient characteristics are displayed in Table 1.

3.1. FOXP3+/CD4+ T-Cell Ratio (But Not Total T-Cell Infiltration or Immune Checkpoint Expression) Is Related to Clinical Disease Severity

T-cells are essential for both the immediate and long-term immune defense against HPV, functioning through direct cytotoxicity, helper activities, and the establishment of immunological memory. To elucidate the intralesional abundance of CD8+, CD4+, and FoxP3+ T-cells, we performed immunohistochemical staining of whole-slide RRP tissue specimens (Figure 1a,b). Furthermore, intralesional expression of inhibitory immune checkpoint molecules PD-L1 and CTLA4 was measured (Figure 1a,b). The mean infiltration of CD4+ T-cells was 153 ± 234 cells/mm2, while the mean infiltration of CD8+ T-cells was 596 ± 724 cells/mm2, and that for FoxP3+ cells was 116 ± 112 FoxP3+ cells/mm2 (Figure 1b). The mean number of cells with expression of CTLA4 was 52 ± 83 cells/mm2, and that for PD-L1 was 92 ± 194 cells/mm2. Notably, expression of CTLA4 and PD-L1 was detected in all tissue specimens. As tissue from multiple consecutive surgeries was available from seven patients, we compared T-cell abundance and immune checkpoint expression in consecutive samples (Figure 1c), but we found no significant differences.
Next, we evaluated the relation of T-cell infiltration and immune checkpoint expression to clinical disease severity. Abundance of CD4+, CD8+, and FoxP3+ T-cells and expression of immune checkpoints CTLA4 and PD-L1 were not associated with the number of surgeries patients had undergone previously (Figure 2a). We analyzed whether immune cell abundance or immune checkpoint expression would influence the intervention-free survival (IFS), defined as the time until the next surgical intervention for RRP is required. Intralesional abundance of CD4-, CD8-, FoxP3-, CTLA4-, or PD-L1-positive cells did not lead to a significantly improved IFS (Figure 2b). Furthermore, we evaluated the ratio of Foxp3+ cells to CD4+ cells. Patients with a low FoxP3/CD4 ratio had fewer previous surgeries compared to those with a high ratio (p = 0.021) (Figure 2c). Determining the ratios of CD8/CD4-, PD-L1/CD8-, PD-L1/CD4-, and CTLA4/CD4-positive cells did not provide additional stratification of patient risk based on T-cell infiltration or immune checkpoint expression.

3.2. Analysis of Stroma and Epithelium Reveals Special Distribution of Intralesional T-Cells

Furthermore, we analyzed whether the spatial distribution of infiltrating lymphocytes would influence the clinical course of RRP. Tissue sections were categorized as either stroma or epithelium, and infiltrating cells within these compartments were analyzed individually (Figure 3a). T-cell abundance and immune checkpoint expression were significantly higher in the stromal compartment compared to epithelium (p < 0.001) (Figure 3b). Immune cell abundance and immune checkpoint expression in RRP epithelium did not correlate with previous surgeries or IFS (Supplementary Figure S1a,b). In the stromal compartment, CD4+, CD8+, and FoxP3+ cells and PD-L1 and CTLA4 expression were not related to clinical disease severity (Supplementary Figure S1c,d).

3.3. Adjuvant Therapy with Cidofovir Is Related to Reduced CD4+ T-Cell Infiltration

In an effort to reduce the number of surgeries needed, many adjuvant therapies have been tested to treat RRP [31]. In our department, intralesional bevacizumab is routinely recommended for patients with high-risk disease, whereas cidofovir is no longer utilized due to its associated adverse effect profile. To investigate whether the efficacy of previous cidofovir or bevacizumab injections are related to a change in intralesional immune cell abundance, we compared patients who did not receive previous local adjuvant therapies with those who were injected with either bevacizumab or cidofovir (Figure 4a). Patients who previously received at least one cidofovir injection had a reduced CD4+ cell infiltration (51 ± 47 vs. 202 ± 245, p = 0.021), but the number of FoxP3+ and CD8+ cells did not differ. The expression of immune checkpoints CTLA4 and PD-L1 was not significantly different between the three groups. In some institutions, prophylactic HPV vaccines Gardasil® or Gardasil9® are recommended as adjuvant therapy for RRP patients. In our cohort, six patients (20%) were vaccinated prior to the surgical intervention. The comparison of CD4+, CD8+, and FoxP3+ cells and immune checkpoints CTLA4 and PD-L1 did not reveal a difference in relation to vaccination status (Figure 4b).

4. Discussion

With the clinical availability of immune checkpoint inhibitors, an interest in the expression and role of immune checkpoints in RRP has developed. Notably, while expression of PD-1 and PD-L1, as well as other immune checkpoints in RRP, has been reported [16,17], to the best of our knowledge, this is the first report that describes the expression of intralesional CTLA4 in RRP.
High counts of FoxP3+ regulatory T-cells (Tregs) are observed in other chronic viral infections of mucosal tissues, including human immunodeficiency viruses (HIV), indicative of a local immunosuppressive microenvironment [32]. Hatam et al. found that functional Tregs (CD4+FoxP3+) are markedly enriched in RRP lesions, with no significant association with clinical disease severity [18]. The presence of Tregs and Treg-promoting cytokines such as interleukin-4 (IL-4), IL-10, and transforming growth factor-β (TGF-β) was significantly higher in aggressive cases of juvenile-onset RRP. We report that patients with a low ratio of FoxP3/CD4-positive cells had a lower number of previous surgeries compared to patients with a high FoxP3/CD4 ratio. This discrepancy may be explained by the small sample sized included in both studies, the application of different detection methods (flow cytometry or immunohistochemistry), or regional differences (North America or Europe). In our cohort, the expression of PD-L1 and the ratio of PD-L1+/CD8+ and PD-L1+/CD4+ cells were not correlated to disease severity or intervention-free survival, consistent with previous reports [15,17]. Furthermore, our results concur with previous studies observing no association of individual intralesional infiltration of CD4+ or FoxP3+ T-cells with disease severity in RRP [17]. CD8+ T-cells play a crucial role in the ability of the immune system to fight virus-infected cells and cancer by releasing cytotoxic molecules such as perforin and granzymes, as well as cytokines like IFN-γ, upon the recognition of MHC I-bound peptide fragments. Notably, in contrast to a previous publication by Ahn et al., CD8+ TILs were not associated with disease severity in our cohort [17]. Possible explanations for this disparity include the limited sample size in both studies, heterogeneous patient populations and regional differences in prevalent HPV types between Europe and the USA [33]. Furthermore, a limitation of the presented data is the unavailability of co-staining of analyzed T-cell markers and immune checkpoint molecules on individual cells, which would have allowed for a more precise characterization of cell populations. Notably, while CD8 and CD4 are established markers of the respective T-cell populations, co-staining with CD3 is commonly employed in immunobiology to verify that positive cells are in fact T-cells, as CD8+/CD3− and CD4+/CD3− non-T-cell populations have been described even though there is no direct evidence of the presence of these cell populations in RRP [34,35].
Separate analyses of T-cell infiltration and immune checkpoint expression in the stromal and epithelial compartment of RRP revealed that the stroma hosts the vast majority of T-cell and immune checkpoint expression. Analyses of the two distinct compartments in RRP are sparsely available [36], but they did not reveal further correlation of T-cell infiltration or immune checkpoint expression with clinical disease severity.
Intralesional application of adjuvant therapies with cidofovir or bevacizumab has shown some efficacy in reducing the frequency of surgical interventions and improving disease control without significantly increasing the risk of dysplasia or malignant transformation in RRP [37,38]. Complementing a recent study published by Solarz et al. [36], we found a significantly lower infiltration of CD4+ T-cells in patients who previously received intralesional cidofovir injections compared to patients with no previous adjuvant therapies. No influence of HPV vaccination with Gardasil® or Gardasil9® on immune cell infiltration was detected. This may be due to the preventive nature of these vaccines as they target the L1 protein, but another factor is the low number of HPV-vaccinated patients present in our cohort. The factors contributing to the low vaccination rate in Germany are likely related to national vaccination policies, the relatively late inclusion of boys in vaccination recommendations, and a high level of vaccine skepticism in the general population.
Recent advances in pharmacologic therapies, including systemic bevacizumab, have complemented the standard treatment of RRP, which primarily relies on repeated surgical debulking of papillomatous lesions [39,40]. While systemic bevacizumab is an efficacious therapy for RRP, life-long treatment is needed. Immune checkpoint inhibitors have shown promising results in the treatment of recurrent respiratory papillomatosis. A phase II study demonstrated that avelumab, a PD-L1 inhibitor, was safe and showed clinical activity in patients with laryngeal RRP, with a significant reduction in the need for surgical interventions [28]. Notably, while anti-PD-L1 therapy has demonstrated clinical activity in patients with laryngeal RRP, as reported by C. Allen et al., all four patients presenting with pulmonary lesions included in this trial did not have a response of pulmonary RRP. One patient with both laryngeal and pulmonary disease demonstrated a response to avelumab therapy in the larynx but no response in the lung. This discordance may suggest a distinct biology of pulmonary manifestations of RRP mediating primary resistance to immune checkpoint therapy. Similar results have been achieved with the PD-1 inhibitors pembrolizumab and nivolumab, highlighting the therapeutic potential of immune checkpoint inhibition in RRP [29,41].
In cancer therapy, the combination of anti-CTLA4 and anti-PD-1 antibodies has demonstrated enhanced anti-tumor efficacy compared to monotherapy in various cancers, including melanoma and non-small-cell lung cancer [42,43]. Mechanistically, the combination therapy induces unique cellular responses that are not observed with monotherapies, marked by an increase in the frequency of activated, terminally differentiated effector CD8+ T-cells and T helper type 1 (Th1)-like CD4+ effector T-cells, which are crucial for effective anti-tumor responses [43]. In RRP, to date, neither anti-CTLA4 therapy alone or in combination with anti-PD-1/PD-L1 antibodies has been evaluated. This may be the case because anti-CTLA4 therapies, such as those involving ipilimumab, are associated with a higher risk of immune-related adverse events (irAEs) [44]. When anti-CTLA4 antibodies are combined with anti-PD-1 antibodies, the risk of severe irAEs is further increased [45]. However, multiple new CTLA4 antibodies aiming to reduce irAEs compared to existing anti-CTLA4 antibodies are in clinical development [46,47]. Regulatory approval of these new drugs may enable the application of anti-CTLA4 antibodies alone or in combination with anti-PD-1 antibodies for the treatment of RRP.

5. Conclusions

We observed that RRP patients with aggressive clinical disease had a higher intralesional ratio of FoxP3/CD4 T-cells. In addition, previous intralesional cidofovir application was related to reduced CD4 T-cell infiltration. Expression of CTLA4 in RRP tissue was detectable in all evaluated cases, providing evidence for the possible study of anti-CTLA4 checkpoint inhibition alone or in combination with other checkpoint inhibitors in RRP.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cells14130985/s1, Figure S1: Individual analysis of epithelial and stromal compartments. Patients are divided into three groups—low, intermediate, and high—according to expression of the respective target molecules (n = 10 per group); (a) workflow for the classification of recurrent respiratory papillomatosis tissue and positive cell detection; investigation of the stromal compartment for the relation of CD4-, CD8-, FoxP3-, CTLA4-, and PD-L1-positive cells with (b) previous surgeries and (c) intervention-free survival; stromal infiltration in relation to lifetime surgeries (d) and intervention-free survival (e); IFS, intervention-free survival; p values calculated by Mann–Whitney test (low vs. high) or log-rank test.; Table S1: Information of antibodies applied for histological staining: A = adenoid; T = tonsil.

Author Contributions

Conceptualization, H.N.C.E., J.P.K., N.W., S.J.S. and K.K.H.; methodology, S.I.L., O.S. and A.Q.; software, S.I.L.; validation, A.Q.; formal analysis, H.N.C.E., S.I.L., M.Z. and J.E.; investigation, H.N.C.E., F.F., A.N., N.W., M.M., K.W. and M.O.; resources, A.Q., H.A.S., J.P.K. and M.C.S.; data curation, H.N.C.E., F.F., M.Z., C.K. and K.K.H.; writing—original draft preparation, H.N.C.E., S.I.L. and K.K.H.; writing—review and editing, F.F., A.N., S.J.S., E.H., J.E., M.A.G.-M., M.T., N.W., K.W., M.M., C.K., M.O., H.A.S., M.Z., A.Q., H.A.S. and M.C.S.; visualization, H.N.C.E., S.I.L., M.T., M.A.G.-M. and E.H.; supervision, H.A.S., J.P.K., A.Q. and K.W.; project administration, O.S. and M.O.; funding acquisition, A.Q. and J.P.K. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki. The institutional review board of the University of Cologne approved this study (Review No. 21-1256, dated 17 August 2021).

Informed Consent Statement

All tissue specimens used in the study were collected during routine surgical treatment of RRP, and written informed consent was obtained from all patients. For patients under 18 years of age at the time of the surgery, parental consent was obtained.

Data Availability Statement

Data are available from the corresponding author upon reasonable request.

Acknowledgments

We thank Wiebke Jeske for her valuable assistance in the course of this research project.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
RRPRecurrent respiratory papillomatosis
IFN-γInterferon-gamma
PD-L1Programmed death-ligand 1
CTLA4Cytotoxic lymphocyte antigen 4
IFSIntervention-free survival
HPVHuman papillomavirus
TIGITT-cell immunoreceptor with Ig and ITIM domains
LAG3Lymphocyte-activation gene 3
TIM3T-cell immunoglobulin and mucin-domain containing-3
ICBImmune checkpoint blockade
TregsRegulatory T-cells
HIVHuman immunodeficiency viruses
IL-4Interleukin-4
TGF-βTransforming growth factor-β
Th1T helper type 1

References

  1. Stanley, M.A. Epithelial Cell Responses to Infection with Human Papillomavirus. Clin. Microbiol. Rev. 2012, 25, 215–222. [Google Scholar] [CrossRef] [PubMed]
  2. Johnson, K.; Derkay, C. Palliative Aspects of Recurrent Respiratory Papillomatosis. Otolaryngol. Clin. N. Am. 2009, 42, 57–70. [Google Scholar] [CrossRef] [PubMed]
  3. Seedat, R.Y.; Schall, R. Age of Diagnosis, Incidence and Prevalence of Recurrent Respiratory Papillomatosis-A South African Perspective. Clin. Otolaryngol. 2018, 43, 533–537. [Google Scholar] [CrossRef] [PubMed]
  4. Omland, T.; Akre, H.; Vãrdal, M.; Brøndbo, K. Epidemiological Aspects of Recurrent Respiratory Papillomatosis: A Population-Based Study. Laryngoscope 2012, 122, 1595–1599. [Google Scholar] [CrossRef]
  5. San Giorgi, M.R.M.; van den Heuvel, E.R.; Tjon Pian Gi, R.E.A.; Brunings, J.W.; Chirila, M.; Friedrich, G.; Golusinski, W.; Graupp, M.; Horcasitas Pous, R.A.; Ilmarinen, T.; et al. Age of Onset of Recurrent Respiratory Papillomatosis: A Distribution Analysis. Clin. Otolaryngol. 2016, 41, 448–453. [Google Scholar] [CrossRef]
  6. Freeman, T.; Erickson, E.; Koch, B.; Young, T.; Allen, D.; Kim, B.; deSilva, B.; Matrka, L. Smoking and Carcinoma Trends in Recurrent Respiratory Papillomatosis Patients. Ann. Otol. Rhinol. Laryngol. 2023, 132, 1380–1385. [Google Scholar] [CrossRef]
  7. Karatayli-Ozgursoy, S.; Bishop, J.A.; Hillel, A.; Akst, L.; Best, S.R.A. Risk Factors for Dysplasia in Recurrent Respiratory Papillomatosis in an Adult and Pediatric Population. Ann. Otol. Rhinol. Laryngol. 2016, 125, 235–241. [Google Scholar] [CrossRef]
  8. Derkay, C.S.; Bluher, A.E. Recurrent Respiratory Papillomatosis: Update 2018. Curr. Opin. Otolaryngol. Head Neck Surg. 2018, 26, 421–425. [Google Scholar] [CrossRef]
  9. Ruan, S.Y.; Chen, K.Y.; Yang, P.C. Recurrent Respiratory Papillomatosis with Pulmonary Involvement: A Case Report and Review of the Literature. Respirology 2009, 14, 137–140. [Google Scholar] [CrossRef]
  10. Benedict, P.A.; Ruiz, R.; Yoo, M.J.; Verma, A.; Ahmed, O.H.; Wang, B.; Dion, G.R.; Voigt, A.; Merati, A.; Rosen, C.A.; et al. Laryngeal Distribution of Recurrent Respiratory Papillomatosis in a Previously Untreated Cohort. Laryngoscope 2018, 128, 138–143. [Google Scholar] [CrossRef]
  11. Matsuzaki, H.; Asai, R.; Makiyama, K. The Predominant Site of Pharyngeal Lesions in Patients with Recurrent Respiratory Papillomatosis. Eur. Arch. Otorhinolaryngol 2022, 279, 4461–4464. [Google Scholar] [CrossRef]
  12. Benedict, P.A.; Kravietz, A.; Achlatis, E.; Wang, B.; Zhang, Y.; Kidane, J.; Harrison, T.; Miller, J.; Drake, V.E.; Best, S.R.; et al. Prospective, Multi-Center Study of the Anatomic Distribution of Recurrent Respiratory Papillomatosis. Laryngoscope 2022, 132, 2403–2411. [Google Scholar] [CrossRef]
  13. Bonagura, V.R.; Hatam, L.J.; Rosenthal, D.W.; De Voti, J.A.; Lam, F.; Steinberg, B.M.; Abramson, A.L. Recurrent Respiratory Papillomatosis: A Complex Defect in Immune Responsiveness to Human Papillomavirus-6 and -11. APMIS 2010, 118, 455–470. [Google Scholar] [CrossRef] [PubMed]
  14. Devoti, J.; Hatam, L.; Lucs, A.; Afzal, A.; Abramson, A.; Steinberg, B.; Bonagura, V. Decreased Langerhans Cell Responses to IL-36γ: Altered Innate Immunity in Patients with Recurrent Respiratory Papillomatosis. Mol. Med. 2014, 20, 372–380. [Google Scholar] [CrossRef] [PubMed]
  15. Liu, T.; Greenberg, M.; Wentland, C.; Sepe, B.; Bowe, S.; Diercks, G.; Huynh, T.; Mino-Kenudson, M.; Schlegel, R.; Kodack, D.; et al. PD-L1 Expression and CD8+ Infiltration Shows Heterogeneity in Juvenile Recurrent Respiratory Papillomatosis. Int. J. Pediatr. Otorhinolaryngol. 2017, 95, 133–138. [Google Scholar] [CrossRef] [PubMed]
  16. Lam, B.; Miller, J.; Kung, Y.J.; Wu, T.C.; Hung, C.F.; Roden, R.; Best, S.R. Profiling of VEGF Receptors and Immune Checkpoints in Recurrent Respiratory Papillomatosis. Laryngoscope 2024, 134, 2819–2825. [Google Scholar] [CrossRef]
  17. Ahn, J.; Bishop, J.A.; Roden, R.B.S.; Allen, C.T.; Best, S.R.A. The PD-1 and PD-L1 Pathway in Recurrent Respiratory Papillomatosis. Laryngoscope 2018, 128, E27–E32. [Google Scholar] [CrossRef]
  18. Hatam, L.J.; DeVoti, J.A.; Rosenthal, D.W.; Lam, F.; Abramson, A.L.; Steinberg, B.M.; Bonagura, V.R. Immune Suppression in Premalignant Respiratory Papillomas: Enriched Functional CD4+Foxp3+ Regulatory T Cells and PD-1/PD-L1/L2 Expression. Clin. Cancer Res. 2012, 18, 1925–1935. [Google Scholar] [CrossRef]
  19. Wang, W.; Xi, Y.; Li, S.; Liu, X.; Wang, G.; Wang, H.; Pei, M.; Zhang, J.; Gui, J.; Ni, X. Restricted Recruitment of NK Cells with Impaired Function Is Caused by HPV-Driven Immunosuppressive Microenvironment of Papillomas in Aggressive Juvenile-Onset Recurrent Respiratory Papillomatosis Patients. J. Virol. 2022, 96, e0094622. [Google Scholar] [CrossRef]
  20. Ballestas, S.A.; Shelly, S.; Soriano, R.M.; Klein, A. Trends in Recurrent Respiratory Papillomatosis Treatment. Acta. Otorrinolaringol. Esp. 2021, 72, 109–120. [Google Scholar] [CrossRef]
  21. Avramov, T.; Vetckova, E.; Nikolova, M.; Valev, D.; Manolova, A.; Tafradgiiska, M.; Kostadinov, D.; Tchalacov, I. Therapeutic Approaches to the Treatment of Recurrent Respiratory Papillomatosis of the Aerodigestive Tract (a Clinical Study). Biotechnol. Biotechnol. Equip. 2014, 28, 668–673. [Google Scholar] [CrossRef] [PubMed]
  22. Borrelli, M.; Nasrollahi, T.; Raskin, J.; Khan, S.; Alexander, R.E. Laryngotracheal Recurrent Papillomatosis: A Case Study and Survey of Surgical and Systemic Management. Ear Nose Throat. J. 2022, 101, 47S–51S. [Google Scholar] [CrossRef]
  23. Chadha, N.K.; James, A.L. Antiviral Agents for the Treatment of Recurrent Respiratory Papillomatosis: A Systematic Review of the English-Language Literature. Otolaryngol. Head Neck Surg. 2007, 136, 863–869. [Google Scholar] [CrossRef]
  24. Leventhal, B.G.; Kashima, H.K.; Mounts, P.; Thurmond, L.; Chapman, S.; Buckley, S.; Wold, D. Long-Term Response of Recurrent Respiratory Papillomatosis to Treatment with Lymphoblastoid Interferon Alfa-N1. Papilloma Study Group. N. Engl. J. Med. 1991, 325, 613–617. [Google Scholar] [CrossRef]
  25. Goon, P.; Sauzet, O.; Schuermann, M.; Oppel, F.; Shao, S.Y.; Scholtz, L.U.; Sudhoff, H.; Goerner, M. Recurrent Respiratory Papillomatosis (RRP)-Meta-Analyses on the Use of the HPV Vaccine as Adjuvant Therapy. NPJ Vaccines 2023, 8, 49. [Google Scholar] [CrossRef]
  26. Litchfield, K.; Reading, J.L.; Puttick, C.; Thakkar, K.; Abbosh, C.; Bentham, R.; Watkins, T.B.K.; Rosenthal, R.; Biswas, D.; Rowan, A.; et al. Meta-Analysis of Tumor- and T Cell-Intrinsic Mechanisms of Sensitization to Checkpoint Inhibition. Cell 2021, 184, 596-614.e14. [Google Scholar] [CrossRef]
  27. Mao, Y.; Xie, H.; Lv, M.; Yang, Q.; Shuang, Z.; Gao, F.; Li, S.; Zhu, L.; Wang, W. The Landscape of Objective Response Rate of Anti-PD-1/L1 Monotherapy across 31 Types of Cancer: A System Review and Novel Biomarker Investigating. Cancer Immunol. Immunother. 2023, 72, 2483–2498. [Google Scholar] [CrossRef]
  28. Allen, C.T.; Lee, S.; Norberg, S.M.; Kovalovsky, D.; Ye, H.; Clavijo, P.E.; Hu-Lieskovan, S.; Schlegel, R.; Schlom, J.; Strauss, J.; et al. Safety and Clinical Activity of PD-L1 Blockade in Patients with Aggressive Recurrent Respiratory Papillomatosis. J. Immunother. Cancer 2019, 7, 119. [Google Scholar] [CrossRef]
  29. Creelan, B.C.; Ahmad, M.U.; Kaszuba, F.J.; Khalil, F.K.; Welsh, A.W.; Ozdemirli, M.; Grant, N.N.; Subramaniam, D.S. Clinical Activity of Nivolumab for Human Papilloma Virus-Related Juvenile-Onset Recurrent Respiratory Papillomatosis. Oncologist 2019, 24, 829–835. [Google Scholar] [CrossRef]
  30. Bankhead, P.; Loughrey, M.B.; Fernández, J.A.; Dombrowski, Y.; McArt, D.G.; Dunne, P.D.; McQuaid, S.; Gray, R.T.; Murray, L.J.; Coleman, H.G.; et al. QuPath: Open Source Software for Digital Pathology Image Analysis. Sci. Rep. 2017, 7, 16878. [Google Scholar] [CrossRef]
  31. Patel, A.; Orban, N. Infantile Recurrent Respiratory Papillomatosis: Review of Adjuvant Therapies. J. Laryngol. Otol. 2021, 135, 958–963. [Google Scholar] [CrossRef] [PubMed]
  32. Shaw, J.M.; Hunt, P.W.; Critchfield, J.W.; McConnell, D.H.; Garcia, J.C.; Pollard, R.B.; Somsouk, M.; Deeks, S.G.; Shacklett, B.L. Increased Frequency of Regulatory T Cells Accompanies Increased Immune Activation in Rectal Mucosae of HIV-Positive Noncontrollers. J. Virol. 2011, 85, 11422–11434. [Google Scholar] [CrossRef] [PubMed]
  33. Clifford, G.M.; Gallus, S.; Herrero, R.; Muñoz, N.; Snijders, P.J.F.; Vaccarella, S.; Anh, P.T.H.; Ferreccio, C.; Hieu, N.T.; Matos, E.; et al. Worldwide Distribution of Human Papillomavirus Types in Cytologically Normal Women in the International Agency for Research on Cancer HPV Prevalence Surveys: A Pooled Analysis. Lancet 2005, 366, 991–998. [Google Scholar] [CrossRef] [PubMed]
  34. Lane, P.J.L.; Gaspal, F.M.C.; Kim, M.Y. Two Sides of a Cellular Coin: CD4+CD3− Cells Regulate Memory Responses and Lymph-Node Organization. Nat. Rev. Immunol. 2005, 5, 655–660. [Google Scholar] [CrossRef]
  35. Quatrini, L.; Della Chiesa, M.; Sivori, S.; Mingari, M.C.; Pende, D.; Moretta, L. Human NK Cells, Their Receptors and Function. Eur. J. Immunol. 2021, 51, 1566–1579. [Google Scholar] [CrossRef]
  36. Solarz, P.; Bodnar, M.; Czech, J.; Mackiewicz–Nartowicz, H.; Sinkiewicz, A.; Szylberg, Ł.; Borowczak, J.; Rutkiewicz, P.; Zwierz, A.; Burduk, P. Assessment of Immunomodulation and Regulation of Cell Cycle in Epithelium and Stroma after Cidofovir Injection in Patients with Recurrent Respiratory Papillomatosis—Pilot Study. J. Med. Virol. 2023, 95, e28303. [Google Scholar] [CrossRef]
  37. Walter, H.; Atfeh, M. Evaluating the Efficacy and Safety of Intralesional Bevacizumab in the Treatment of Recurrent Respiratory Papillomatosis: A Systematic Review. Int. J. Pediatr. Otorhinolaryngol. 2024, 186, 112138. [Google Scholar] [CrossRef]
  38. Clamp, P.J.; Saunders, M.W. Systematic Review of Intralesional Cidofovir Dosing Regimens in the Treatment of Recurrent Respiratory Papillomatosis. Int. J. Pediatr. Otorhinolaryngol. 2013, 77, 323–328. [Google Scholar] [CrossRef]
  39. Best, S.R.; Bock, J.M.; Fowler, N.B.; Raabe, E.H.; Klein, A.M.; Laetsch, T.W.; McClellan, K.; Rinkel, R.N.P.M.; Saba, N.F.; Sidell, D.R.; et al. A Consensus Statement on the Administration of Systemic Bevacizumab in Patients with Recurrent Respiratory Papillomatosis. Laryngoscope 2024, 134, 5041–5046. [Google Scholar] [CrossRef]
  40. So, R.J.; Rayle, C.; Joo, H.H.; Huang, E.Y.; Seiwert, T.Y.; Raabe, E.H.; Best, S.R. Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Institution’s Experience. Laryngoscope 2024, 134, 3253–3259. [Google Scholar] [CrossRef]
  41. Strohl, M.P.; Rosen, C.A. Stabilization of Recurrent Respiratory Papillomatosis with Pembrolizumab Therapy: A Case Report. J. Voice 2023, 37, 637.e1–637.e3. [Google Scholar] [CrossRef] [PubMed]
  42. Rotte, A. Combination of CTLA-4 and PD-1 Blockers for Treatment of Cancer. J. Exp. Clin. Cancer Res. 2019, 38, 255. [Google Scholar] [CrossRef] [PubMed]
  43. Wei, S.C.; Anang, N.A.A.S.; Sharma, R.; Andrews, M.C.; Reuben, A.; Levine, J.H.; Cogdill, A.P.; Mancuso, J.J.; Wargo, J.A.; Pe’er, D.; et al. Combination Anti–CTLA-4 plus Anti–PD-1 Checkpoint Blockade Utilizes Cellular Mechanisms Partially Distinct from Monotherapies. Proc. Natl. Acad. Sci. USA 2019, 116, 22699–22709. [Google Scholar] [CrossRef]
  44. Bertrand, A.; Kostine, M.; Barnetche, T.; Truchetet, M.E.; Schaeverbeke, T. Immune Related Adverse Events Associated with Anti-CTLA-4 Antibodies: Systematic Review and Meta-Analysis. BMC Med. 2015, 13, 211. [Google Scholar] [CrossRef] [PubMed]
  45. Wang, D.Y.; Salem, J.E.; Cohen, J.V.; Chandra, S.; Menzer, C.; Ye, F.; Zhao, S.; Das, S.; Beckermann, K.E.; Ha, L.; et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. JAMA Oncol. 2018, 4, 1721–1728. [Google Scholar] [CrossRef]
  46. He, K.; Carbone, D.P.; McKean, M.; Balaraman, R.; Shah, S.; Arrowsmith, E.; Peguero, J.A.; Joshi, R.; He, A.R.; Milillo, A.; et al. Safety and Clinical Activity of Target-Preserving Anti-CTLA-4 Antibody ONC-392 as Monotherapy in NSCLC Patients Who Progressed on PD(L)1-Targeted Immunotherapy. J. Clin. Oncol. 2023, 41, 9024. [Google Scholar] [CrossRef]
  47. Thomas, J.S.; Selfridge, J.E.; Albany, C.; Taylor, M.H.; Mehmi, I.; Kwatra, V.; Hu-Lieskovan, S.; de Souza, P.L.; Llorin-Sangalang, J.D.; Aysola, K.; et al. Phase 1 Study of BA3071, an Anti–CTLA-4 Conditionally Active Biologic, in Combination with Nivolumab in Advanced Solid Tumors. J. Clin. Oncol. 2024, 42, 2602. [Google Scholar] [CrossRef]
Cells 14 00985 g001
Figure 1. CD4-, CD8-, FoxP3-, CTLA4-, and PD-L1-positive immune cells infiltrate recurrent respiratory papillomatosis (RRP) tissue. Tissue samples of patients with RRP were stained for the indicated markers by immunohistochemistry. (a) Representative images of tissue samples with high and low expression of the indicated molecules. (b) Number of positively stained cells/mm2 displayed as individual values, mean, and standard deviation (n = 30). (c) CD4-, CD8-, FoxP3-, CTLA-4- and PD-L1-positive cells/mm2 in consecutive surgical specimens (n = 7); ns, not significant; mm, millimeter. Significant differences were calculated by Mann–Whitney test.
Figure 1. CD4-, CD8-, FoxP3-, CTLA4-, and PD-L1-positive immune cells infiltrate recurrent respiratory papillomatosis (RRP) tissue. Tissue samples of patients with RRP were stained for the indicated markers by immunohistochemistry. (a) Representative images of tissue samples with high and low expression of the indicated molecules. (b) Number of positively stained cells/mm2 displayed as individual values, mean, and standard deviation (n = 30). (c) CD4-, CD8-, FoxP3-, CTLA-4- and PD-L1-positive cells/mm2 in consecutive surgical specimens (n = 7); ns, not significant; mm, millimeter. Significant differences were calculated by Mann–Whitney test.
Cells 14 00985 g001
Cells 14 00985 g002
Figure 2. Correlation of T-cell abundance and immune checkpoint expression with clinical severity reveals more previous surgeries in patients with a high ratio of FoxP3+/CD4+ cells. Patients are divided into three groups—low, intermediate, and high—according to expression of the respective target molecules (n = 10 per group). (a) Number of previous lifetime surgeries of patients with respect to immune cell infiltration and immune checkpoint expression. (b) Intervention-free survival in relation to the expression of CD4, CD8, FoxP3, CTLA4, and PD-L1. (c) Lifetime surgeries in relation to the intralesional ratio of CD8+/CD4+ cells, FoxP3+/CD4+ cells, PD-L1+/CD8+ cells, PD-L1+/CD4+ cells, and CTLA4+/CD4+ cells. IFS, intervention-free survival. Significant differences were calculated by Mann–Whitney test (comparing low vs. high groups) and log-rank test.
Figure 2. Correlation of T-cell abundance and immune checkpoint expression with clinical severity reveals more previous surgeries in patients with a high ratio of FoxP3+/CD4+ cells. Patients are divided into three groups—low, intermediate, and high—according to expression of the respective target molecules (n = 10 per group). (a) Number of previous lifetime surgeries of patients with respect to immune cell infiltration and immune checkpoint expression. (b) Intervention-free survival in relation to the expression of CD4, CD8, FoxP3, CTLA4, and PD-L1. (c) Lifetime surgeries in relation to the intralesional ratio of CD8+/CD4+ cells, FoxP3+/CD4+ cells, PD-L1+/CD8+ cells, PD-L1+/CD4+ cells, and CTLA4+/CD4+ cells. IFS, intervention-free survival. Significant differences were calculated by Mann–Whitney test (comparing low vs. high groups) and log-rank test.
Cells 14 00985 g002
Cells 14 00985 g003
Figure 3. Immune cell infiltration is more abundant in stromal tissue than in epithelial tissue. (a) Workflow for the classification of recurrent respiratory papillomatosis tissue stroma and epithelium, as well as positive cell detection. (b) Investigation of the distribution of CD4-, CD8-, FoxP3-, CTLA4-, and PD-L1-positive cells within the stromal and epithelial compartments of RRP tissue; mm, millimeter. Statistical differences were calculated by Mann–Whitney test.
Figure 3. Immune cell infiltration is more abundant in stromal tissue than in epithelial tissue. (a) Workflow for the classification of recurrent respiratory papillomatosis tissue stroma and epithelium, as well as positive cell detection. (b) Investigation of the distribution of CD4-, CD8-, FoxP3-, CTLA4-, and PD-L1-positive cells within the stromal and epithelial compartments of RRP tissue; mm, millimeter. Statistical differences were calculated by Mann–Whitney test.
Cells 14 00985 g003
Cells 14 00985 g004
Figure 4. Cidofovir treatment influences CD4+ T-cell infiltration in RRP. Tissue samples of RRP patients were analyzed by immunohistochemistry for the expression of the indicated markers. (a) Samples without previous adjuvant therapy (n = 15) were compared to samples with either previous bevacizumab (n = 8) or cidofovir (n = 7); statistical differences were calculated by Mann–Whitney test (none vs. bevacizumab or cidofovir). (b) Prophylactic HPV vaccination (Gardasil® or Gardasil 9 ®) (n = 6) compared to unvaccinated (n = 24) patients; significant differences were calculated by Mann–Whitney test.
Figure 4. Cidofovir treatment influences CD4+ T-cell infiltration in RRP. Tissue samples of RRP patients were analyzed by immunohistochemistry for the expression of the indicated markers. (a) Samples without previous adjuvant therapy (n = 15) were compared to samples with either previous bevacizumab (n = 8) or cidofovir (n = 7); statistical differences were calculated by Mann–Whitney test (none vs. bevacizumab or cidofovir). (b) Prophylactic HPV vaccination (Gardasil® or Gardasil 9 ®) (n = 6) compared to unvaccinated (n = 24) patients; significant differences were calculated by Mann–Whitney test.
Cells 14 00985 g004
Table 1. Patient characteristics and clinical demographics of the recurrent respiratory papillomatosis cohort. All data were collected retrospectively from patients with available tissue specimens; n, number; NA, not applicable.
Table 1. Patient characteristics and clinical demographics of the recurrent respiratory papillomatosis cohort. All data were collected retrospectively from patients with available tissue specimens; n, number; NA, not applicable.
Patient Characteristics RRP Cohort n = 30 (100%)
SexMale17 (57%)
Female13 (43%)
AgeMedian (range)32 (1–61)
OnsetJuvenile4 (13%)
Adult26 (87%)
Surgical interventionsMedian (range)3 (1–21)
Previous adjuvant treatment Yes15 (50%)
No15 (50%)
HPV vaccinationYes6 (20%)
No24 (80%)
Involvement of tracheaYes2 (7%)
No28 (93%)
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Eckel, H.N.C.; Lyu, S.I.; Faste, F.; Sharma, S.J.; Nobis, A.; Wuerdemann, N.; Ziogas, M.; Mayer, M.; Suchan, M.C.; Wennhold, K.; et al. Local T-Cell Dysregulation and Immune Checkpoint Expression in Human Papillomavirus-Mediated Recurrent Respiratory Papillomatosis. Cells 2025, 14, 985. https://doi.org/10.3390/cells14130985

AMA Style

Eckel HNC, Lyu SI, Faste F, Sharma SJ, Nobis A, Wuerdemann N, Ziogas M, Mayer M, Suchan MC, Wennhold K, et al. Local T-Cell Dysregulation and Immune Checkpoint Expression in Human Papillomavirus-Mediated Recurrent Respiratory Papillomatosis. Cells. 2025; 14(13):985. https://doi.org/10.3390/cells14130985

Chicago/Turabian Style

Eckel, Hans N. C., Su Ir Lyu, Frederik Faste, Shachi J. Sharma, Anne Nobis, Nora Wuerdemann, Maria Ziogas, Marcel Mayer, Malte C. Suchan, Kerstin Wennhold, and et al. 2025. "Local T-Cell Dysregulation and Immune Checkpoint Expression in Human Papillomavirus-Mediated Recurrent Respiratory Papillomatosis" Cells 14, no. 13: 985. https://doi.org/10.3390/cells14130985

APA Style

Eckel, H. N. C., Lyu, S. I., Faste, F., Sharma, S. J., Nobis, A., Wuerdemann, N., Ziogas, M., Mayer, M., Suchan, M. C., Wennhold, K., Garcia-Marquez, M. A., Thelen, M., Hagen, E., Eßer, J., Klasen, C., Siefer, O., Otte, M., Schloesser, H. A., Klussmann, J. P., ... Hansen, K. K. (2025). Local T-Cell Dysregulation and Immune Checkpoint Expression in Human Papillomavirus-Mediated Recurrent Respiratory Papillomatosis. Cells, 14(13), 985. https://doi.org/10.3390/cells14130985

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop